Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 3Multiple Myeloma 2Amyloidosis 2Paraproteinemias 1Monoclonal Gammopathy of Undetermined Significance 1Amyloid Neuropathies, Familial 1

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 7Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene × Clear all
NCT07624760 2026-06-03

MGUS-PET

University of Zurich

Phase NA Not yet recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡